Therini Bio Trials New Eye Injection That Targets Both Fibrin and VEGF in Diabetic Patients
A novel antibody targeting inflammation in diabetic eye disease enters Phase 1b trials, with early data expected by end of 2026.
Summary
Therini Bio has begun dosing patients in a Phase 1b trial of THN391, a new antibody treatment for diabetic macular edema — a leading cause of vision loss in people with diabetes. Unlike existing therapies that only block VEGF, a protein driving abnormal blood vessel growth, THN391 also targets fibrin's inflammatory activity while leaving normal blood clotting intact. Patients receive three monthly eye injections across three dose groups, with safety and vision outcomes tracked using retinal thickness and visual acuity measures. Preclinical data suggest the drug performs comparably to current VEGF blockers. The company also has a next-generation bispecific candidate combining both mechanisms. Results are expected in Q4 2026.
Detailed Summary
Diabetic macular edema is a serious complication of diabetes that causes fluid buildup in the retina, progressively damaging central vision. Current standard-of-care treatments block a protein called VEGF, but many patients don't respond fully or see their disease return. Therini Bio is testing a new approach that targets a different driver of retinal damage: fibrin-driven inflammation.
THN391 is a humanized monoclonal antibody engineered to block only the inflammatory portion of fibrin — a protein involved in both clotting and chronic inflammation — without disrupting normal coagulation. This precision targeting is significant because fibrin accumulation in retinal blood vessels contributes to leakage and neuroinflammation, which VEGF blockers alone don't address.
The Phase 1b trial is enrolling patients across three dose cohorts, each receiving three intravitreal injections once monthly. Researchers will track retinal central subfield thickness, visual acuity, and exploratory biomarkers to assess both safety and biological activity. A 2026 preclinical paper in the Journal of Neuroinflammation reported THN391 matched VEGF antagonist performance in containing retinal leakage, giving early confidence in the mechanism.
Beyond THN391, Therini Bio has named THN622 as its lead next-generation candidate — a bispecific antibody designed to block both fibrin inflammation and VEGF simultaneously. The company believes this dual approach could improve response rates, extend durability of effect, and potentially prevent fibrosis, a scarring process that contributes to irreversible retinal damage and vision loss. Fibrin-targeting may also be relevant to Alzheimer's disease, where vascular neuroinflammation plays a comparable role.
Caveats apply: this is an early-stage trial focused on safety and preliminary efficacy signals, not a large randomized study. Phase 1b results expected in Q4 2026 will be hypothesis-generating rather than definitive. Patients with diabetic eye disease should continue current therapies and monitor this space as clinical evidence develops.
Key Findings
- THN391 targets fibrin's inflammatory role without disrupting normal blood clotting, a novel mechanism for diabetic eye disease.
- Preclinical data show THN391 matched VEGF blockers in reducing retinal leakage in animal models.
- Phase 1b trial uses three monthly intravitreal injections across three dose groups; safety data expected Q4 2026.
- Next-generation bispecific THN622 combines fibrin and VEGF blockade, potentially improving durability and preventing retinal fibrosis.
- Fibrin-targeting immunotherapy may also have applications in Alzheimer's disease through shared vascular neuroinflammation pathways.
Methodology
This is a news report summarizing a company press release about a Phase 1b clinical trial initiation. The source, Longevity.Technology, is a health and longevity media outlet; the claims reflect company-provided data and cite one preclinical peer-reviewed paper in the Journal of Neuroinflammation. Independent validation of efficacy claims is not yet available.
Study Limitations
Phase 1b trials are primarily designed to assess safety and dosing, not to confirm efficacy at scale. All efficacy claims currently rest on preclinical animal data from a single 2026 paper. Readers should await peer-reviewed human trial results before drawing conclusions about clinical benefit.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.